Stryker to acquire Amplitude Vascular Systems to expand peripheral vascular portfolio

Stryker has signed a definitive agreement to acquire Amplitude Vascular Systems (AVS), further strengthening its position in the peripheral vascular space by adding next-generation intravascular lithotripsy (IVL) technology. The move adds innovative revascularization capabilities to Stryker’s growing portfolio focused on arterial disease treatment.

AVS, a privately held medical technology company based in Boston, has been developing an advanced IVL platform designed to treat calcified peripheral arterial disease (PAD), a condition in which calcium build-up narrows blood vessels and makes intervention procedures more complex.

According to the company, the acquisition will complement Stryker’s existing peripheral vascular offerings once the technology receives clearance in applicable markets. The addition aligns with Stryker’s broader strategy to expand its presence in vascular intervention and provide physicians with more advanced tools for complex procedures.

Next-generation IVL technology for calcified lesions

At the core of the acquisition is AVS’s IVL platform, which uses pulsed CO₂-generated pressure waves delivered uniformly through an IVL balloon catheter to fracture calcium deposits within arteries and improve luminal gain. The system is designed to enhance catheter deliverability, speed up treatment, and improve overall therapy efficiency.

IVL continues to gain traction as one of the fastest-growing technologies in cardiovascular intervention, particularly for treating calcified peripheral and coronary lesions. As physicians increasingly adopt calcium modification approaches in complex vascular procedures, demand for such technologies is expected to continue growing.

“This acquisition represents an important step in advancing our vision to build a comprehensive peripheral vascular platform and address significant unmet clinical needs,” said Kevin Lobo, Chair and CEO of Stryker.

“Combining this innovation with Stryker’s scale and clinical expertise, we believe we can help expand treatment options for physicians and improve care for patients with calcified peripheral arterial disease.”

The transaction remains subject to customary closing conditions. Until the deal is completed, Stryker and AVS will continue to operate as separate entities and proceed with business as usual.

Source

Stryker

Up Next: MedTech World North America 2026 | West Palm Beach 

Following the success of its flagship event in Dubai earlier in February, MedTech World is now heading to Florida for its next major edition. The North America event in West Palm Beach will bring together founders, investors, healthcare leaders, and policymakers to explore commercialization pathways, cross-border collaboration, and capital deployment in MedTech. 

If you are looking to be part of this milestone North America edition, you can engage in ways that align with your goals: 

• Present 
• Speak 
• Deploying capital? Join as an investor 
• Partner with us 
• Attend as a delegate